WO2005073199A1 - Derives d'indazole utilises comme inhibiteurs de la lipase hormono-sensible - Google Patents

Derives d'indazole utilises comme inhibiteurs de la lipase hormono-sensible Download PDF

Info

Publication number
WO2005073199A1
WO2005073199A1 PCT/EP2005/000365 EP2005000365W WO2005073199A1 WO 2005073199 A1 WO2005073199 A1 WO 2005073199A1 EP 2005000365 W EP2005000365 W EP 2005000365W WO 2005073199 A1 WO2005073199 A1 WO 2005073199A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
formula
indazole
ring system
aryl
Prior art date
Application number
PCT/EP2005/000365
Other languages
German (de)
English (en)
Inventor
Gerhard Zoller
Stefan Petry
Günter Müller
Hubert Heuer
Karl-Heinz Baringhaus
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Priority to DE502005011241T priority Critical patent/DE502005011241D1/de
Priority to NZ548872A priority patent/NZ548872A/en
Priority to EP05700954A priority patent/EP1713779B1/fr
Priority to JP2006549989A priority patent/JP4714158B2/ja
Priority to AU2005209366A priority patent/AU2005209366A1/en
Priority to BRPI0507370-7A priority patent/BRPI0507370A/pt
Priority to CA002554524A priority patent/CA2554524A1/fr
Priority to AT05700954T priority patent/ATE505460T1/de
Publication of WO2005073199A1 publication Critical patent/WO2005073199A1/fr
Priority to IL176912A priority patent/IL176912A/en
Priority to NO20063925A priority patent/NO20063925L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present invention relates to indazole derivatives of the general formulas I or II, their pharmaceutically acceptable salts and their use as medicaments. ,
  • Indazole derivatives for stimulating the cannabinoid receptor are described in WO 03/035005 and derivatives of 3-amino-indazolecarboxylic acid in DE 24 58 965. Furthermore, phenylcarbamoyl-indazoles are described in WO 2004/046090 and 3-amino-5-phenylindazole-1-carboxylic acid amide in US 2004/0097485, these two documents being published only after submission of the present priority application.
  • the invention relates to indazole derivatives of the general formulas I or II,
  • Y is -O- or -N (RI);
  • R is hydrogen, halogen, (C 1 -C 6 ) -alkyl, (C 1 -C 3 ) -alkyl-O- (C 1 -C 3 ) -alkylene, hydroxy, (C 1 -C 6 ) -alkylmercapto, amino, (C 1 -C 6 -alkylamino, i- (C 2 -C ⁇ ) - Alkylamino, mono (C ⁇ -C6) -alkylaminocarbonyl, di- (C 2 -Cs) - alkylaminocarbonyl, COOR4, cyano, trifluoromethyl, (CrC 6) - alkylsulfonyl, (CrC 6) alkylsulfinyl, aminosulfonyl, nitro, pentafluorosulfanyl, (C 6 -C 10) -aryl, (C 5 -C 12 ) -Heteroaryl, CO-NR 2
  • R1 H (CC 6) -alkyl, benzyl
  • R2 H (CrC 6) alkyl, (C 1 -C 4) alkyl-phenyl, (C 6 -C ⁇ 0) -aryl, wherein aryl is phenyl and optionally substituted by halogen, (C ⁇ -C6) alkyl, (C 1 -C 4 ) -alkyloxy, hydroxy, (CC 6 ) -alkylmercapto, amino, (C 1 -C 6 ) -alkylamino, C 1 -C 12 -alkylamino, C 1 -C 6 -alkylaminocarbonyl, di- (C 2 -C 8 ) -alkylaminocarbonyl, (C 1 -C 6 ) -alkyloxycarbonyl, cyano, trifluoromethyl, trifluoromethyloxy, (C 1 -C 6 ) -alkylsulfonyl, aminosulfonyl, nitro, or tetramethyl-
  • R 3 is H, (CC 6 ) -alkyl
  • R4 is hydrogen, (CC 6 ) alkyl, benzyl; R 5 (C 1 -C 6 ) alkyl, halogen, trifluoromethyl, COOR 4, cyclopropyl, cyclopropylene;
  • R is hydrogen, halogen, (CC 6 ) -alkyl, hydroxy, amino, COOR 4, trifluoromethyl, (CC 6 ) -alkylsulfonyl, nitro, pentafluorosulfanyl, (C ⁇ -Cio) -aryl, CO-NR 2 R 3, O-CO-NR 2 R 3 or O -CO- (C 1 -C 6 ) -alkylene-CO-O- (C 1 -C 6 ) -alkyl;
  • R1 H (CC 6) -alkyl, benzyl
  • R2 (CC 6) alkyl, benzyl, (C 6 -C ⁇ 0) -aryl or tetrahydronaphthalene tetramethyl-;
  • R 3 is H, (C 1 -C 6 ) -alkyl
  • R 4 is hydrogen, (C 1 -C 6 ) -alkyl or benzyl
  • R 5 is (C 1 -C 6 ) -alkyl, halogen, trifluoromethyl, COOR 4, cyclopropyl, cyclopropylene.
  • R is hydrogen, halogen, nitro, hydroxy or (C 1 -C 6 ) -alkyl
  • R1 is H or (dC 6) alkyl
  • R 2 (CC 6 ) -alkyl, benzyl or (C 6 -C -ol) -aryl;
  • R 2 and R 3 together with the nitrogen atom bearing them, can form a monocyclic, saturated 5- to 6-membered ring system or a bicyclic saturated or partially unsaturated 9- to 10-membered ring system whose individual members of the ring systems are selected from an atom or an atomic group -CHR5-, -NR5-, can be replaced; and
  • R 5 is (C 1 -C 6 ) -alkyl or cyclopropyl.
  • R is hydrogen, halogen, (CC 6 ) alkyl, hydroxy, amino, COOR 4, trifluoromethyl, (C 1 -C 6 ) alkylsulfonyl, nitro, pentafluorosulfanyl, (C 6 -C 10 ) aryl, CO-NR 2 R 3, O-CO-NR 2 R 3 or O-CO- (CC 5 ) -alkylene-CO-O- (CC 6 ) -alkyl;
  • R1 H (CC 6 ) alkyl or benzyl
  • R2 (dC 6) alkyl, (C 6 -C ⁇ 0) -aryl or tetramethyl-tetrahydronaphthalene;
  • R 3 is H, (C 1 -C 6 ) -alkyl
  • R 4 is hydrogen, (C 1 -C 6 ) -alkyl, benzyl
  • R 5 is (dC 6 ) alkyl, halogen, trifluoromethyl, COOR 4, cyclopropyl, cyclopropylene.
  • NR2R3 is piperidine containing the atomic element CHR5 in the 4 position.
  • the invention relates to compounds of the formulas I or II, in the form of their salts, racemates, racemic mixtures and pure enantiomers, and to their diastereomers and mixtures thereof.
  • the alkyl radicals in the substituents R, R 1, R 2, R 3, R 4, R 5 can be both straight-chain and branched.
  • Halogen is fluorine, chlorine, bromine or iodine, especially fluorine or chlorine.
  • aryl is meant a monocyclic or bicyclic aromatic ring system containing 6 to 10 carbon atoms in the ring or rings and optionally substituted independently with one to four substituents, preferably one or two substituents as described herein can be.
  • Heteroaryl is a mono- or bicyclic aromatic ring system having 5 to 12 ring members, wherein at least one atom in the ring system is a heteroatom from the series N, O and S and the remaining atoms are C atoms.
  • Pharmaceutically acceptable salts are particularly suitable for medical applications because of their higher water solubility compared to the starting or basic compounds. These salts must have a pharmaceutically acceptable anion or cation.
  • Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention are salts of inorganic acids such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric and organic acids, e.g.
  • Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth salts (such as magnesium and calcium salts) and salts of trometamol (2-amino-2-hydroxymethyl-1,3-propanediol), diethanolamine, lysine or ethylenediamine ,
  • Salts with a non-pharmaceutically acceptable anion, such as trifluoroacetate, are also within the scope of the invention as useful intermediates for the preparation or purification of pharmaceutically acceptable salts and / or for use in non-therapeutic, for example, in vitro applications.
  • physiologically functional derivative refers to any physiologically acceptable derivative of a compound of formula I or II of the invention, for example, an ester capable of (direct or indirect) administration when administered to a mammal, such as man Compound of formula I or II or to form an active metabolite thereof.
  • the physiologically functional derivatives also include prodrugs of the compounds according to the invention, as described, for example, in H. Okada et al., Chem. Pharm. Bull. 1994, 42, 57-61. Such prodrugs can be metabolized in vivo to a compound of the invention. These prodrugs may or may not be effective.
  • the compounds of the invention may also be in various polymorphic forms, e.g. as amorphous and crystalline polymorphic forms. All polymorphic forms of the compounds of the invention are within the scope of the invention and are a further aspect of the invention.
  • the compounds of the general formulas I or II according to the invention have a surprising inhibitory effect on the hormone sensitive lipase, HSL, an allosteric enzyme in adipocytes, which is inhibited by insulin and for the degradation of fats in fat cells and thus for the conversion of fatty components in the Bloodstream is responsible.
  • HSL hormone sensitive lipase
  • An inhibition of this enzyme thus corresponds to an insulin-like action of the compounds of the invention, which ultimately leads to a reduction of free fatty acids in the blood and blood sugar. So you can are used in derangements of the metabolism such as non-insulin-dependent diabetes mellitus, the diabetic syndrome and direct damage to the pancreas.
  • Diabetes mellitus especially type 2 diabetes, including the prevention of associated sequelae. Special aspects are: - hyperglycemia, - improvement of insulin resistance, - improvement of glucose tolerance, - protection of pancreatic beta-cells - prevention of macro- and microvascular diseases
  • dyslipidemias and their consequences e.g. Atherosclerosis, coronary heart disease, cerebrovascular diseases etc, particularly those (but not limited to) characterized by one or more of the following factors: high plasma triglyceride, high postprandial plasma triglyceride concentrations low HDL cholesterol concentration low ApoA Lipoprotein Concentrations - High LDL Cholesterol Concentrations - Small Density LDL Cholesterol Particles - High ApoB Lipoprotein Concentrations
  • Various other conditions that may be associated with the metabolic syndrome include: - Obesity (obesity), including abdominal obesity - Thrombosis, stages of hypercoagulability and thrombosis (arterial and venous) - High blood pressure - Heart failure, such as (but not limited to) post-myocardial infarction, hypertensive heart disease or cardiomyopathy
  • Atherosclerosis such as (but not limited to) coronary sclerosis including angina pectoris or myocardial infarction, stroke - vascular restenosis or reversion - inflammatory bowel disease, such as Crohn's disease and ulcerative colitis - Pancreatitis -
  • Other inflammatory conditions - Retinopathy - Adipose cell tumors - Fat cell carcinomas, such as liposarcomas - Solid tumors and neoplasias, such as (but not limited to) carcinomas of the stomach Intestinal tract, liver, biliary tract and pancreas, endocrine tumors, lung, kidney and urinary tract, genital tract, prostate carcinoma etc.
  • Dermatitides e.g. seborrheic dermatitis or light dermatitis - keratitis and keratoses, e.g. seborrheic keratoses, senile keratoses, actinic keratosis, photo-induced keratoses or follicular keratosis
  • HPV Human papilloma viral infections, e.g. venereal papillomata, viral warts, e.g. Molluscum contagiosum, leukoplakia
  • - skin cancer e.g. Basal cell carcinomas, melanomas or cutaneous T-cell lymphomas
  • PCOS Polycystic Ovarian Syndrome
  • Lupus erythematosus or inflammatory rheumatic diseases, e.g. Rheumatoid arthritis
  • ARDS - Acute Respiratory Distress Syndrome
  • the amount of compound of the invention required to achieve the desired biological effect is dependent upon a number of factors, eg, the specific compound chosen, the intended use, the mode of administration, and the clinical condition of the patient.
  • the daily dose ranges from 0.3 mg to 100 mg (typically from 3 mg to 50 mg) per day per kilogram of body weight, eg, 3 -10 mg / kg / day.
  • an intravenous dose may range from 0.3 mg to 1.0 mg / kg, which may suitably be administered as an infusion of 10 ng to 100 ng per kilogram per minute.
  • Suitable infusion solutions for these purposes may contain, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg per milliliter.
  • Single doses may contain, for example, from 1 mg to 10 g of the active ingredient.
  • ampoules for injections of from 1 mg to 100 mg, and orally administrable unit dose formulations such as tablets or capsules may contain from 0.05 to 1000 mg, typically from 0.5 to 600 mg.
  • the compounds according to formula I or II may themselves be used as a compound, but they are preferably present with a tolerable carrier in the form of a pharmaceutical composition.
  • the carrier must of course be compatible in the sense that it is compatible with the other ingredients of the composition and is not harmful to the patient.
  • the carrier may be a solid or a liquid, or both, and is preferably formulated with the compound as a single dose, for example, as a tablet, which may contain from 0.05% to 95% by weight of the active ingredient.
  • Other pharmaceutically active substances may also be present, including other compounds of the invention.
  • the pharmaceutical compositions according to the invention can be prepared by one of the known pharmaceutical methods, which consist essentially in that the ingredients are mixed with pharmacologically acceptable carriers and / or excipients.
  • compositions according to the invention are those which are suitable for oral, rectal, topical, peroral (eg sublingual) and parenteral (eg subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable mode of administration in each individual case is the nature and severity of the treatment State and on the nature of the particular compound used in accordance with formula I or II is dependent.
  • coated formulations and coated slow release formulations are within the scope of the invention. Preference is given to acid and enteric formulations. Suitable enteric coatings include cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methacrylic acid methyl ester.
  • Suitable pharmaceutical preparations for oral administration may be in separate units, such as capsules, cachets, lozenges or tablets, each containing a certain amount of the compound of formula I or II; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion.
  • these compositions may be prepared by any suitable pharmaceutical method comprising a step of contacting the active ingredient and the carrier (which may consist of one or more additional ingredients).
  • the compositions are prepared by uniformly and homogeneously mixing the active ingredient with a liquid and / or finely divided solid carrier, after which the product is molded, if necessary.
  • a tablet can be made by compressing or molding a powder or granules of the compound, optionally with one or more additional ingredients.
  • Pressed tablets may be prepared by tableting the compound in free-flowing form, such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, and / or one or more surface active / dispersing agents in a suitable machine.
  • Shaped tablets can by molding the powdered, moistened with an inert liquid diluent compound can be prepared in a suitable machine.
  • compositions suitable for peroral (sublingual) administration include lozenges containing a compound of Formula I or II with a flavoring, usually sucrose and gum arabic or tragacanth, and lozenges containing the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.
  • Suitable pharmaceutical compositions for parenteral administration preferably comprise sterile aqueous preparations of a compound according to formula I or II which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although the administration may also be subcutaneous, intramuscular or intradermal as an injection. These preparations may preferably be prepared by mixing the compound with water and rendering the resulting solution sterile and isotonic with the blood. Injectable compositions of the invention generally contain from 0.1% to 5% by weight of the active compound.
  • Suitable pharmaceutical compositions for rectal administration are preferably as single dose suppositories. These can be prepared by mixing a compound according to formula I or II with one or more conventional solid carriers, for example cocoa butter, and shaping the resulting mixture.
  • Suitable pharmaceutical compositions for topical application to the skin are preferably as an ointment, cream, lotion, paste, spray, aerosol or oil.
  • Vaseline, lanolin, polyethylene glycols, alcohols, and combinations of two or more of these substances can be used as the carrier.
  • the active ingredient is generally present at a level of from 0.1% to 15% by weight of the composition, for example from 0.5% to 2%.
  • Transdermal administration is also possible.
  • Suitable pharmaceutical compositions for transdermal applications may exist as single patches suitable for long-term close contact with the epidermis of the patient. Such patches suitably contain the active ingredient in an optionally buffered aqueous solution, dissolved and / or dispersed in an adhesive or dispersed in a polymer.
  • a suitable active ingredient concentration is about 1% to 35%, preferably about 3% to 15%.
  • the active ingredient can be released by electrotransport or iontophoresis as described, for example, in Pharmaceutical Research, 2 (6): 318 (1986).
  • the compounds of the formulas I and II are distinguished by favorable effects on metabolic disorders. They have a positive influence on the fat and sugar metabolism, in particular they lower the levels of FFA, glycerol and triglycerides and are suitable for the prevention and treatment of type II diabetes and atherosclerosis as well as their diverse secondary diseases.
  • the compounds according to the invention can be administered alone or in combination with one or more further pharmacologically active substances which, for example, have beneficial effects on metabolic disorders or diseases frequently associated therewith.
  • Such medicines are, for example, 1. anti-hypertensive drugs, antidiabetic drugs, 2. drugs for the treatment of dyslipidemia, 3. anti-atherosclerotic drugs, 4. anti-adiposity, 5. anti-inflammatory agents 6. drugs for the treatment of malignant tumors 7. antithrombotic agents 8. active ingredients for treatment of hypertension 9. drugs for the treatment of heart failure; and 10. drugs for the treatment and / or prevention of complications caused by diabetes or associated with diabetes.
  • the administration of the active ingredient combination can be carried out either by separate administration of the active ingredients to the patient or in the form of combination preparations in which several active ingredients are present in a pharmaceutical preparation.
  • Examples include:
  • Antidiabetics are disclosed, for example, in the Red List 2001, Chapter 12 or the USP Dictionary of US and International Drug Names, US Pharmacopeia, Rockville 2003.
  • Antidiabetics include all insulins and insulin derivatives such as, for example, Lantus ® (see www.lantus.com) or Apidra ®, and other fast-acting insulins (see US 6,221, 633), GLP-1 receptor modulators as described in WO 01/04146 described , or even such as those disclosed in WO 98/08871 by Novo Nordisk A / S.
  • the orally active hypoglycemic agents preferably include sulphonylfharneins, biguanides, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, glucagon antagonists, oral GLP-1 agonists, DPP-IV inhibitors, potassium channel openers such as those described in WO 97/26265 and US Pat WO 99/03861, insulin sensitizers, inhibitors of liver enzymes involved in the stimulation of gluconeogenesis and / or glycogenolysis, modulators of glucose uptake, lipid metabolism altering compounds that alter the lipid composition of the blood, compounds containing the compounds Reduce food intake or intake, PPAR and PXR modulators, and drugs that act on the ATP-dependent potassium channel of beta cells.
  • the compounds of the formula I or II are administered in combination with insulin.
  • the compounds of formula I or II are administered in combination with substances having an influence on hepatic glucose production, e.g. Glycogen phosphorylase inhibitors (see: WO 01/94300, WO 02/096864, WO 03/084923, WO 03/084922, WO 03/104188)
  • substances having an influence on hepatic glucose production e.g. Glycogen phosphorylase inhibitors (see: WO 01/94300, WO 02/096864, WO 03/084923, WO 03/084922, WO 03/104188)
  • the compounds of formula I or II are used in combination with a sulphonylurea, e.g. Tolbutamide, glibenclamide, glipizide or glimepiride.
  • a sulphonylurea e.g. Tolbutamide, glibenclamide, glipizide or glimepiride.
  • the compounds of formula I or II are administered in combination with an agent which acts on the ATP-dependent potassium channel of the beta cells, e.g. Tolbutamide, glibenclamide, glipizide, glimepiride or repaglinide.
  • an agent which acts on the ATP-dependent potassium channel of the beta cells e.g. Tolbutamide, glibenclamide, glipizide, glimepiride or repaglinide.
  • the compounds of formula I or II are used in combination with a biguanide, e.g. Metformin, administered.
  • a biguanide e.g. Metformin
  • the compounds of formula I or II are used in combination with a meglitinide, e.g. Repaglinide, administered.
  • a meglitinide e.g. Repaglinide
  • the compounds of formula I or II are used in combination with a thiazolidinedione such as, for example, ciglitazone, pioglitazone, rosiglitazone or those described in WO 97/41097 by Dr. med. Reddy's Research Foundation disclosed compounds, particularly 5 - [[4 - [(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy] phenyl] methyl] -2,4-thiazolidinedione.
  • a thiazolidinedione such as, for example, ciglitazone, pioglitazone, rosiglitazone or those described in WO 97/41097 by Dr. med. Reddy's Research Foundation disclosed compounds, particularly 5 - [[4 - [(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy] phenyl] methyl] -2,4-
  • the compounds of the formula I or II are described in combination with a DPPIV inhibitor, as described, for example, in WO98 / 19998, WO99 / 61431, WO99 / 67278, WO99 / 67279, WO01 / 72290, WO 02/38541, WO03 / 040174 , in particular P 93/01 (1-cyclopentyl-3-methyl-1-oxo-2-one pentanammonium chloride), P-31/98, LAF237 (1- [2- [3-hydroxyadamant-1-ylamino) acetyl] pyrrolidine-2- (S) -carbonitrile), TSO21 ((2S, 4S) -4-fluoro -1 - [[(2-hydroxy-1, 1-dimethylethyl) amino] acetyl] -pyrrolidine-2-carbonitrile monobenzene sulfonate)
  • the compounds of formula I or II in combination with a PPARgamma agonist e.g. Rosiglitazone, pioglitazone.
  • the compounds of formula I or II are used in combination with a ⁇ -glucosidase inhibitor, e.g. Miglitol or acarbose, administered.
  • a ⁇ -glucosidase inhibitor e.g. Miglitol or acarbose
  • the compounds of formula I or II are used in combination with more than one of the aforementioned compounds, e.g. in combination with a sulphonylurea and metformin, a sulphonylurea and acarbose, repaglinide and metformin, insulin and a sulphonylurea,
  • the compounds of formula I or II are administered in combination with an HMGCoA reductase inhibitor such as lovastatin, fluvastatin, pravastatin, simvastatin, ivastatin, itavastatin, atorvastatin, rosuvastatin.
  • an HMGCoA reductase inhibitor such as lovastatin, fluvastatin, pravastatin, simvastatin, ivastatin, itavastatin, atorvastatin, rosuvastatin.
  • the compounds of the formula I or II are administered in combination with a bile acid absorption inhibitor (see, for example, US Pat. No. 6,245,744, US Pat. No. 6,221,897, US Pat. No. 6,277,831, EP 0683 773, EP 0683 774).
  • the compounds of formula I or II are used in combination with a polymeric bile acid adsorbent, e.g. Cholestyramine, colesevelam.
  • a polymeric bile acid adsorbent e.g. Cholestyramine, colesevelam.
  • the compounds of the formula I or II are administered in combination with a cholesterol absorption inhibitor, such as e.g. in WO 0250027, or Ezetimibe, Tiqueside, Pamaqueside.
  • a cholesterol absorption inhibitor such as e.g. in WO 0250027, or Ezetimibe, Tiqueside, Pamaqueside.
  • the compounds of formula I or II are administered in combination with an LDL receptor inducible (see, e.g., U.S. 6,342,512).
  • the compounds of formula I or II in combination with bulking agents preferably insoluble bulking agents
  • bulking agents preferably insoluble bulking agents
  • Caromax is a carob-containing product of the company Nutrinova, Nutrition Specialties & Food Ingredients GmbH, Industriepark availability, 65926 Frankfurt / Main) administered.
  • Combination with Caromax ® is possible in one preparation or by separate administration of compounds of the formula I and Caromax ®.
  • Caromax ® can also be administered in the form of food, such as in baked goods or muesli bars.
  • the compounds of the formula I or II are administered in combination with a PPARalpha agonist.
  • the compounds of formula I or II are used in combination with a mixed PPAR alpha / gamma agonist such as AZ 242 (Tesaglitazar, (S) -3- (4- [2- (4-methanesulfonyloxyphenyl) ethoxy] phenyl) -2-ethoxypropionic acid), BMS 298585 (N - [(4-methoxyphenoxy) carbonyl] -N - [[4 - [2- (5-methyl-2-phenyl-4-oxazolyl) ethoxy] phenyl] methyl] glycine) or as described in WO 99/62872, WO 99/62871, WO 01/40171, WO 01/40169, WO96 / 38428, WO 01/81327, WO 01/21602, WO 03/020269, WO 00/64888 or WO 00/64876.
  • AZ 242 Tesaglitazar, (
  • the compounds of formula I or II are used in combination with a fibrate, e.g. Fenofibrate, gemfibrozil, clofibrate, bezafibrate.
  • a fibrate e.g. Fenofibrate, gemfibrozil, clofibrate, bezafibrate.
  • the compounds of the formula I or II are administered in combination with nicotinic acid or niacin.
  • the compounds of formula I or II are administered in combination with a CETP inhibitor, e.g. CP-529, 414 (torcetrapib).
  • a CETP inhibitor e.g. CP-529, 414 (torcetrapib).
  • the compounds of the formula I or II are administered in combination with an ACAT inhibitor
  • the compounds of formula I or I are administered in combination with an MTP inhibitor, e.g. Implitapide, administered.
  • an MTP inhibitor e.g. Implitapide
  • the compounds of the formula I or II are administered in combination with an antioxidant.
  • the compounds of the formula I or II are administered in combination with a lipoprotein lipase inhibitor.
  • the compounds of the formula I or II are administered in combination with an ATP citrate lyase inhibitor. In one embodiment of the invention, the compounds of the formula I or II are administered in combination with a squalene synthetase inhibitor.
  • the compounds of the formula I or II are administered in combination with a lipoprotein (a) antagonist.
  • the compounds of formula I or II are used in combination with a lipase inhibitor, e.g. Orlistat, administered.
  • a lipase inhibitor e.g. Orlistat
  • the other active ingredient is fenfluramine or dexfenfluamine.
  • the other active ingredient is sibutramine.
  • the compounds of formula I or II are used in combination with CART modulators (see “cocaine-amphetamine-regulated transcript-influenza-influencing energy metabolism, anxiety and gastric emptying in mice" Asakawa, A, et al., M.: Hormones and Metabolie Research (2001), 33 (9), 554-558), NPY antagonists eg naphthalene-1-sulfonic acid ⁇ 4 - [(4-amino-quinazolin-2-ylamino) -methyl] -cyclohexylmethyl ⁇ -amide; hydrochloride (CGP 71683A)), MC4 agonists (eg, 1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid [2- (3a-benzyl-2-methyl-3-oxo-2,3 , 3a, 4,6,7-hexahydro-pyrazolo [4,3-c] pyridin-5-yl
  • PPAR modulators e.g., WO 00/78312
  • RXR modulators e.g., TR- ⁇ agonists.
  • the further active ingredient is leptin.
  • the other active ingredient is dexamphetamine, amphetamine, mazindol or phentermine.
  • the compounds of formula I or II are administered in combination with drugs having effects on the cardiovascular and blood vessel systems, e.g. ACE inhibitors (e.g., ramipril), drugs acting on the angiotensin-renin system, calcium antagonists, beta-blockers, etc.
  • drugs having effects on the cardiovascular and blood vessel systems e.g. ACE inhibitors (e.g., ramipril), drugs acting on the angiotensin-renin system, calcium antagonists, beta-blockers, etc.
  • the compounds of formula I or II are administered in combination with anti-inflammatory drugs. In one embodiment, the compounds of formula I or II are administered in combination with medicaments used for cancer therapy and cancer prevention.
  • NAG NBD monoacylglyceride
  • phosphatidylcholine and 6 mg phosphatidylinositol are dissolved in 1 ml chloroform each.
  • 10 mg NAG are dissolved in 1 ml Chlorofom.
  • Two parts of phosphatidylinositol solution (eg 83.5 ⁇ l) and one part of phosphatidylcholine solution (eg 41.5 ⁇ l) and 100 ⁇ l of NAG solution are pipetted together in plastic scintillation vials (final test concentration: 0.0375 mg phospholipid / ml, 0.05 mg / NAG / ml).
  • the chloroform (225 ⁇ l total volume) is completely removed by blowing over with an N2 stream.
  • the dried substrate can be stored at 4 ° C for up to 3 days.
  • the dried substrate is taken up in 20 ml of assay buffer (25 mM Tris / HCl, pH 7.4, 150 mM NaCl) and two ultrasound treatments with an ultrasonic rod (Branson Sonifier Type II, standard microtip). : 1st treatment setting 2, 2 x 1 min, between each 1 min on ice; 2. Treatment setting 4, 2 x 1 min, between each 1 min on ice.
  • the color of the substrate solution changes from yellow (extinction maximum 481 nm) to red (extinction maximum 550 nm) by intercalation of NAGs between the phospholipid molecules of the vesicles / micelles.
  • the solution is still 15 min on Ice incubated.
  • the assay is performed in 1.5 ml Eppendorf tubes or 96-well plates for 60 min at 30 ° C.
  • 10 ⁇ l of the test substance are placed in assay buffer (25 mM Tris / HCl, pH 7.4, 150 mM NaCl) in the presence of 16.6% DMSO.
  • 180 ⁇ l of the substrate solution (20 ⁇ g / ml phosphatidylcholine, 10 ⁇ g / ml phosphatidylinositol, 50 ⁇ g / ml NAG in assay buffer) are added.
  • the products of the HSL reaction are analyzed by phase separation / thin layer chromatography.
  • the incubation mixture 200 ⁇ l total volume, see indirect NAG assay
  • the incubation mixture in 2 ml Eppendorf tubes with 1.3 ml of methanol / chloroform / heptane (10: 9: 7) and then with 0.4 ml of 0.1 M NaOH.
  • the phase separation by centrifugation 800xg, 20 min,
  • aqueous phase is dried (SpeedVae) and then taken up in 50 ⁇ l of tetrahydrofuran. 5 ⁇ l samples are applied to silica gel Si-60 plates (Merck). The chromatography is with 78 ml
  • the amount of released fluorescent NBD fatty acid is determined by phosphorimaging (Molecular Dynamics, Storm 840 and ImageQuant software) at an excitation wavelength of 460 nm and emission wavelength of 540-560 nm.
  • Isolated rat fat cells are obtained from epididymal adipose tissue from untreated male rats (Wistar, 220-250 g) by collagenase treatment according to published procedures (eg S. Nilsson et al., Anal. Biochem., 158, 1986, 399-407, G. Fredrikson et Chem. 256, 1981, 6311-6320, H. Tornquist et al., J. Biol. Chem. 251, 1976, 813-819).
  • the fat cells from 10 rats are washed three times by flotation with in each case 50 ml of homogenization buffer (25 ml Tris / HCl, pH 7.4, 0.25 M sucrose, 1 mM EDTA, 1 mM DTT, 10 ⁇ g / ml leupeptin, 10 ⁇ g / ml antipain, 20 ⁇ g / ml pepstatin) and finally taken up in 10 ml homogenization buffer.
  • the fat cells are homogenized in a Teflon-in-glass homogenizer (Braun-Melsungen) by 10 strokes at 1500 rpm and 15 ° C.
  • the homogenate is centrifuged (Sorvall SM24 tube, 5000 rpm, 10 min, 4 ° C).
  • the shelter between the fat layer above and the pellet is removed and the centrifugation repeated.
  • the resulting shelter is again centrifuged (Sorvall SM24 tube, 20000 rpm, 45 min, 4 ° C).
  • the shelter is removed and treated with 1 g of heparin-Sepharose (Pharmacia Biotech, CL-6B, washed 5 times with 25 mM Tris / HCl, pH 7.4, 150 mM NaCl).
  • the HSL is eluted with a volume of equilibration buffer containing 0.5 M potassium phosphate, then dialyzed (see above) and concentrated 5-10 fold by ultrafiltration (Amicon Diaflo PM 10 filter) at 4 ° C.
  • the partially purified HSL can be stored at -70 ° C for 4 to 6 weeks.
  • trioleoylglycerol in toluene
  • 6.8 ⁇ M unlabeled trioleoylglycerol 0.6 mg phospholipids (phosphatidylcholine / phosphatidylinositol 3: 1 w / v) are mixed, dried over N 2 and then dissolved in 2 ml 0.1 M KPi (pH 7.0) was recorded by sonication (Branson 250, microtip, setting 1-2, 2 x 1 min every 1 min).
  • Substances are usually tested in four independent approaches.
  • the inhibition of the enzymatic activity of HSL by a test substance is determined by comparison with a non-inhibited control reaction.
  • the IC50 value is calculated using an inhibition curve with at least 10 concentrations of the test substance.
  • the software package GRAPHIT, Elsevier BIOSOFT is used. In this test, the compounds of Examples 1 to 103 showed
  • the preparation of the compounds of the general formulas I or II according to the invention is carried out by methods known per se, e.g. by acylation of substituted or unsubstituted indazoles III with carbamoyl chlorides IV (method A), or in two stages by reaction of indazoles III with phosgene or equivalents such as trichloromethyl chloroformate or carboxylic acid trichloromethyl ester and further reaction of the Indazolcarbonklarechlorids obtained with amines or anilines (Method B).
  • R3 is hydrogen
  • bases such as pyridine, triethylamine, sodium hydroxide solution or alkali metal carbonates to accelerate them.
  • the reactions can be carried out in wide temperature ranges. In general, it has been found to be advantageous to work at 0 ° C to the boiling point of the solvent used.
  • the solvents used are, for example, methylene chloride, THF, DMF, toluene, ethyl acetate, n-heptane, dioxane, diethyl ether or pyridine.
  • strong bases such as lithium hydride, sodium hydride or potassium tert-butoxide have also proven useful in aprotic solvents such as THF or DMF.
  • indazoles or corresponding azabased derivatives used as starting compounds III are commercially available or can be prepared by literature methods (for example L. Baiocchi, G. Corsi Synthesis (1978), 633-648, I. Sekikawa et al., J. Het Chem. (1973), 931-932).
  • the compounds of the general formulas I or II are separated and purified by generally known methods by chromatography.
  • Example 5B were hydrogenated in 15 ml of ethanol in the presence of 10% palladium / carbon at 2 bar hydrogen pressure for 2.5 h at room temperature. The catalyst was filtered off with suction and the filtrate was concentrated. Yield: 21 mg (76%), M + H +: 275.2.
  • Example 1 was repeated with 2 g (14.9 mmol) of 1H-indazol-3-ol.
  • A 4-methyl-piperidine-1-carboxylic acid 1 H-indazol-3-yl ester
  • C 2- (4-methyl-piperidine-1-carbonyl) -1,2-dihydro-indazol-3-one.
  • Example 9 :
  • Carbonic acid ditrichloromethyl ester (840 mg, 2.83 mmol) was dissolved in 30 ml of methylene chloride and slowly added in an ice bath with 2.06 ml (25.24 mmol) of pyridine added. After 30 min. 4-trifluoromethyl-piperidine hydrochloride (1.45 g, 7.65 mmol) was added slowly in portions. After removing the ice bath was still 90 min. stirred, the precipitate filtered off with suction, washed with n-heptane and the filtrate was concentrated. The product obtained (1.9 g) still contains some salt and was directly reacted further.
  • Trifluoromethyl-piperidine-1-carboxylic acid 4-methyl-3- (4-trifluoromethyl-piperidine-1-carbonyloxy) -1H-pyrazolo [3,4-b] pyridin-6-yl ester, M + H +: 524.20; 106 mg (3%) of 4-trifluoromethyl-piperidine-1-carboxylic acid 6-hydroxy-4-methyl-1- (4-trifluoromethylpiperidine-1-carbonyl) -1H-pyrazolo [3,4-b] pyridine 3-yl ester, M + H +: 524.52; 54 mg (1.3%) 4-trifluoromethyl-piperidine-1-carboxylic acid 4-methyl-3- (4-trifluoromethyl-piperidine-1-carbonyloxy) -1- (4-trifluoromethylpiperidine-1-carbonyl) -1H pyrazolo [3,4-b] pyridin-6-yl ester, M + H +: 703.36.
  • Example 13 4-Methyl-piperazine-1-carboxylic acid 4-methyl-3- (4-trifluoromethyl-piperidine-1-carbonyloxy) -1H-pyrazolo [3,4-b] pyridin-6-yl ester; compound with trifluoro-acetic acid 4-Trifluoromethyl-piperidine-1-carboxylic acid 6-hydroxy-4-methyl-1H-pyrazolo [3,4-b] pyridin-3-yl ester (300 mg, 0.87 mmol), 4-methylpiperazine-1 Carbonyl chloride hydrochloride (191 mg, 0.96 mmol) and triethylamine (0.48 mL, 3.48 mmol) were dissolved in 10 mL pyridine for 5 h at room temp.
  • 2-Amino-4-fluoro-benzoic acid 25 g, 161.2 mmol was added to 250 ml of water and 39 ml of conc. Hydrochloric acid suspended. At 0 ° C, sodium nitrite (11.2 g, 161.2 mmol) in 30 ml of water was added dropwise below 10 ° C. After 30 min. at room temp. were
  • 2-Amino-terephthalic acid dimethyl ester (5 g, 23.9 mmol) was dissolved in 40 ml of water and 6 ml of conc. Hydrochloric acid hydrochloric acid dissolved. At 0 ° C, sodium nitrite (1.65 g, 23.9 mmol) in 5 ml of water was added dropwise below 10 ° C. After 30 min. at room temp. Sodium sulfite (11.02 g, 87.42 mmol) in 40 mL of water was added. After stirring for 1 h, 10 ml of conc. Hydrochloric acid added and allowed to stand overnight. The mixture was then heated at 80 ° C. for 24 h, cooled and adjusted to pH 5.5 with sodium hydroxide solution. The precipitate was filtered off with suction and dried. Yield: 2.29 g, (54%), M + H +: 179.04.

Abstract

L'invention concerne des dérivés d'indazole de formule générale (I) ou (II), (les significations étant données dans la description), leurs sels pharmaceutiquement acceptables et leur utilisation comme médicaments.
PCT/EP2005/000365 2004-02-02 2005-01-15 Derives d'indazole utilises comme inhibiteurs de la lipase hormono-sensible WO2005073199A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DE502005011241T DE502005011241D1 (de) 2004-02-02 2005-01-15 Indazolderivate als inhibitoren der hormon-sensitiven lipase
NZ548872A NZ548872A (en) 2004-02-02 2005-01-15 Indazole derivatives as inhibitors of hormone-sensitive lipases
EP05700954A EP1713779B1 (fr) 2004-02-02 2005-01-15 Derives d'indazole utilises comme inhibiteurs de la lipase hormono-sensible
JP2006549989A JP4714158B2 (ja) 2004-02-02 2005-01-15 ホルモン感受性リパーゼの阻害剤としてのインダゾール誘導体
AU2005209366A AU2005209366A1 (en) 2004-02-02 2005-01-15 Indazole derivatives as inhibitors of hormone-sensitive lipases
BRPI0507370-7A BRPI0507370A (pt) 2004-02-02 2005-01-15 derivados de indazol como inibidores da lipase sensìvel ao hormÈnio
CA002554524A CA2554524A1 (fr) 2004-02-02 2005-01-15 Derives d'indazole utilises comme inhibiteurs de la lipase hormono-sensible
AT05700954T ATE505460T1 (de) 2004-02-02 2005-01-15 Indazolderivate als inhibitoren der hormon- sensitiven lipase
IL176912A IL176912A (en) 2004-02-02 2006-07-17 Indazole derivatives as inhibitors of hormone-sensitive lipases
NO20063925A NO20063925L (no) 2004-02-02 2006-09-01 Indazolderivater som inhibitorer av hormonsensitiv lipase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004005172A DE102004005172A1 (de) 2004-02-02 2004-02-02 Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
DE102004005172.0 2004-02-02

Publications (1)

Publication Number Publication Date
WO2005073199A1 true WO2005073199A1 (fr) 2005-08-11

Family

ID=34801466

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/000365 WO2005073199A1 (fr) 2004-02-02 2005-01-15 Derives d'indazole utilises comme inhibiteurs de la lipase hormono-sensible

Country Status (27)

Country Link
US (2) US7528155B2 (fr)
EP (1) EP1713779B1 (fr)
JP (1) JP4714158B2 (fr)
KR (1) KR20060128958A (fr)
CN (1) CN1914180A (fr)
AR (1) AR047520A1 (fr)
AT (1) ATE505460T1 (fr)
AU (1) AU2005209366A1 (fr)
BR (1) BRPI0507370A (fr)
CA (1) CA2554524A1 (fr)
CR (1) CR8487A (fr)
DE (2) DE102004005172A1 (fr)
DO (1) DOP2005000011A (fr)
EC (1) ECSP066750A (fr)
HN (1) HN2005000039A (fr)
IL (1) IL176912A (fr)
MA (1) MA28338A1 (fr)
MY (1) MY143407A (fr)
NO (1) NO20063925L (fr)
NZ (1) NZ548872A (fr)
PE (1) PE20050690A1 (fr)
RU (1) RU2370491C2 (fr)
SG (1) SG149891A1 (fr)
TW (1) TW200536535A (fr)
UY (1) UY28735A1 (fr)
WO (1) WO2005073199A1 (fr)
ZA (1) ZA200605311B (fr)

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131233A1 (fr) 2005-06-09 2006-12-14 Sanofi-Aventis Derives de benzooxazol-2-one servant d'inhibiteurs de lipases et de phospholipases
WO2006131231A1 (fr) 2005-06-09 2006-12-14 Sanofi-Aventis Dérivés d'azolopyridin-2-one en tant qu'inhibiteurs de lipases et de phospholipases
WO2007042178A1 (fr) * 2005-10-12 2007-04-19 Sanofi-Aventis Derives d'indazole de diacyle constituant des inhibiteurs de lipases et de phospholipases
WO2007045392A1 (fr) * 2005-10-19 2007-04-26 Sanofi-Aventis Derives de triazolopyridine utilises comme inhibiteurs de lipases et de phospholipases
WO2007110216A1 (fr) * 2006-03-28 2007-10-04 Sanofi-Aventis Dérivés d'azolopyridin-3-one utiles comme inhibiteurs de la lipase endothéliale
WO2007110215A1 (fr) * 2006-03-28 2007-10-04 Sanofi-Aventis Dérivés d'imidazopyridin-2-one utiles comme inhibiteurs de la lipase endothéliale
WO2008017381A1 (fr) 2006-08-08 2008-02-14 Sanofi-Aventis Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituée, son procédé de fabrication, médicament contenant ce composé et son utilisation
WO2008122357A1 (fr) * 2007-04-05 2008-10-16 Sanofi-Aventis 5-oxo-isoxazoles utilisés comme inhibiteurs de lipases et de phospholipases
FR2915199A1 (fr) * 2007-04-18 2008-10-24 Sanofi Aventis Sa Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
FR2915198A1 (fr) * 2007-04-18 2008-10-24 Sanofi Aventis Sa Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
WO2009021740A2 (fr) 2007-08-15 2009-02-19 Sanofis-Aventis Nouvelles tétrahydronaphtalines substituées, leurs procédés de préparation et leur utilisation comme médicaments
WO2010003624A2 (fr) 2008-07-09 2010-01-14 Sanofi-Aventis Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation
US7709509B2 (en) 2004-04-01 2010-05-04 Sanofi-Aventis Deutschland Gmbh Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
JP2010524907A (ja) * 2007-04-18 2010-07-22 サノフイ−アベンテイス トリアゾロピリジンカルボキサミド誘導体、その調製およびその治療的使用
WO2011023754A1 (fr) 2009-08-26 2011-03-03 Sanofi-Aventis Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, substances pharmaceutiques comprenant ces composés et leur utilisation
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
WO2011161030A1 (fr) 2010-06-21 2011-12-29 Sanofi Dérivés de méthoxyphényle à substitution hétérocyclique par un groupe oxo, leur procédé de production et leur utilisation comme modulateurs du récepteur gpr40
WO2012004270A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés 1,3-propanedioxyde à substitution spirocyclique, procédé de préparation et utilisation comme médicament
WO2012004269A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés d'acide ( 2 -aryloxy -acétylamino) - phényl - propionique, procédé de production et utilisation comme médicament
WO2012010413A1 (fr) 2010-07-05 2012-01-26 Sanofi Acides hydroxy-phényl-hexiniques substitués par aryloxy-alkylène, procédé de production et utilisation comme médicament
WO2012031383A1 (fr) * 2010-09-06 2012-03-15 中国科学院广州生物医药与健康研究院 Composés amide
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120050A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, médicaments contenant ces composés et leur utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120051A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
WO2012120058A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120057A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2567959A1 (fr) 2011-09-12 2013-03-13 Sanofi Dérivés d'amide d'acide 6-(4-Hydroxy-phényl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2013128465A1 (fr) * 2011-12-22 2013-09-06 Connexios Life Sciences Pvt. Ltd. Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci
WO2014017938A3 (fr) * 2012-07-27 2014-03-20 BIAL - PORTELA & Cª, S.A. Procédé pour la synthèse de composés d'urée substitués
WO2015035113A1 (fr) 2013-09-06 2015-03-12 Karos Pharmaceuticals, Inc. Composés spirocycliques en tant qu'inhibiteurs de la tryptophane hydroxylase
WO2015089137A1 (fr) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines comme inhibiteurs de la tryptophan hydroxylase
WO2016109501A1 (fr) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Composés amides utilisés en tant qu'inhibiteurs de la tryptophane hydroxylase
US9549915B2 (en) 2012-07-24 2017-01-24 Bial-Portela & Ca, S.A. Urea compounds and their use as enzyme inhibitors
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
US10266530B2 (en) 2016-09-09 2019-04-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
US10501447B2 (en) 2013-07-24 2019-12-10 BIAL-PORTELA & Cᵃ, S.A. Imidazolecarboxamides and their use as FAAH inhibitors
WO2020099929A1 (fr) 2018-11-14 2020-05-22 Roivant Sciences Gmbh Inhibiteur de composé spirocyclique cristallin de tryptophane hydroxylase 1 (tph1) pour le traitement de maladies ou de troubles associés à la sérotonine périphérique
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US10800761B2 (en) 2018-02-20 2020-10-13 Incyte Corporation Carboxamide compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
US11014929B2 (en) 2016-09-09 2021-05-25 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US11066394B2 (en) 2019-08-06 2021-07-20 Incyte Corporation Solid forms of an HPK1 inhibitor
US11111247B2 (en) 2018-09-25 2021-09-07 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US11242343B2 (en) 2016-09-09 2022-02-08 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US11406624B2 (en) 2017-02-15 2022-08-09 Incyte Corporation Pyrazolopyridine compounds and uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564804T3 (es) * 2004-02-12 2016-03-29 Mitsubishi Tanabe Pharma Corporation Compuesto de indazol y uso farmacéutico del mismo
EP2157859A4 (fr) * 2007-06-19 2011-01-12 Takeda Pharmaceutical Composés d'indazole permettant d'activer la glucokinase
DE102007043281A1 (de) 2007-09-11 2009-05-28 Sebastian Dr. med. Chakrit Bhakdi Vorrichtung, Materialien und Verfahren zur Hochgradientenmagnetseparation biologischen Materials
SG11201807053TA (en) 2016-03-07 2018-09-27 X Zell Inc Compositions and methods for identifying rare cells

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2458965A1 (de) 1974-12-13 1976-06-16 Bayer Ag 3-amino-indazolcarbonsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
WO2003035005A2 (fr) 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: nouvelle classe de ligands cannabimimetiques efficaces
WO2003068773A1 (fr) * 2002-02-12 2003-08-21 Glaxo Group Limited Derives de pyrazolopyridine
WO2003097610A1 (fr) * 2002-05-17 2003-11-27 Pharmacia Italia S.P.A. Derives d'aminoindazole agissant comme inhibiteurs de kinase, methode d'obtention et compositions pharmaceutiques les renfermant
WO2004022544A1 (fr) * 2002-09-05 2004-03-18 Aventis Pharma S.A. Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
US20040097485A1 (en) 2002-10-31 2004-05-20 Tularik Inc. Antiinflammation agents
WO2004046090A2 (fr) 2002-11-21 2004-06-03 Neurosearch A/S Nouveaux derives d'acide aryl ureido benzoique et leur utilisation
WO2004062662A1 (fr) * 2002-12-12 2004-07-29 Aventis Pharma S.A. Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB681376A (en) * 1949-11-23 1952-10-22 Geigy Ag J R Manufacture of heterocyclic carbamic acid derivatives and their use as agents for combating pests
FR2663336B1 (fr) * 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9305641D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
IL125071A0 (en) 1996-01-17 1999-01-26 Novo Nordisk As Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives their preparation and use
CA2264243C (fr) 1996-08-30 2004-10-05 Novo Nordisk A/S Derives de glp-1
DK0958296T3 (da) 1996-12-31 2003-08-18 Reddys Lab Ltd Dr Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
EP0983249B1 (fr) * 1997-05-08 2002-03-13 Pfizer Products Inc. Procedes et produits intermediaires pour la preparation de derives d'indazole substitues
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
CA2294830A1 (fr) 1997-07-16 1999-01-28 John Bondo Hansen Derives de 1,2,4-thiadiazine fusionnee, leur preparation et utilisation
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
JP4377545B2 (ja) * 1997-10-28 2009-12-02 カストロール・リミテッド グラフト共重合体の製造方法
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
WO2000063208A1 (fr) 1999-04-16 2000-10-26 Novo Nordisk A/S Imidazoles substitues, leur preparation et utilisation
HUP0200997A3 (en) 1999-04-28 2003-03-28 Sanofi Aventis Deutschland Tri-aryl acid derivatives as ppar receptor ligands and pharmaceutical compositions containing them
DK1177187T3 (da) * 1999-04-28 2007-10-15 Sanofi Aventis Deutschland Diarylsyrederivater som PPAR-receptorligander
WO2000066585A1 (fr) 1999-04-30 2000-11-09 Neurogen Corporation Derives 9h-pyrimido[4,5-b]indoles: ligands specifiques de crf1
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
DE60029446T2 (de) 1999-06-18 2007-02-08 Merck & Co., Inc. Arylthiazolidindione und aryloxazolidindion-derivate
PT1204654E (pt) 1999-07-29 2003-11-28 Lilly Co Eli Benzofurilpiperazinas agonistas do receptor 5-ht2c da serotonina
DE50011035D1 (de) * 1999-09-01 2005-09-29 Aventis Pharma Gmbh Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
KR100502876B1 (ko) 2000-04-28 2005-07-21 아사히 가세이 파마 가부시키가이샤 신규 이환성 화합물
PL208515B1 (pl) * 2001-08-31 2011-05-31 Sanofi Aventis Deutschland Pochodne diarylocykloalkilowe, środki lecznicze zawierające te związki oraz ich zastosowanie jako aktywatorów PPAR
WO2004093872A1 (fr) * 2003-03-31 2004-11-04 Eli Lilly And Company Utilisation de derives amides d'acide 3-oxo-1,3-dihydro-indazole-2-carboxylique comme inhibiteurs de la phospholipase

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2458965A1 (de) 1974-12-13 1976-06-16 Bayer Ag 3-amino-indazolcarbonsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
WO2003035005A2 (fr) 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: nouvelle classe de ligands cannabimimetiques efficaces
WO2003068773A1 (fr) * 2002-02-12 2003-08-21 Glaxo Group Limited Derives de pyrazolopyridine
WO2003097610A1 (fr) * 2002-05-17 2003-11-27 Pharmacia Italia S.P.A. Derives d'aminoindazole agissant comme inhibiteurs de kinase, methode d'obtention et compositions pharmaceutiques les renfermant
WO2004022544A1 (fr) * 2002-09-05 2004-03-18 Aventis Pharma S.A. Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
US20040097485A1 (en) 2002-10-31 2004-05-20 Tularik Inc. Antiinflammation agents
WO2004046090A2 (fr) 2002-11-21 2004-06-03 Neurosearch A/S Nouveaux derives d'acide aryl ureido benzoique et leur utilisation
WO2004062662A1 (fr) * 2002-12-12 2004-07-29 Aventis Pharma S.A. Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
H. OKADA ET AL., CHEM. PHARM. BULL., vol. 42, 1994, pages 57 - 61
LAN ET AL: "Structure-Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 42, no. 4, 1999, pages 769 - 776, XP002145465, ISSN: 0022-2623 *

Cited By (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709509B2 (en) 2004-04-01 2010-05-04 Sanofi-Aventis Deutschland Gmbh Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists
WO2006131231A1 (fr) 2005-06-09 2006-12-14 Sanofi-Aventis Dérivés d'azolopyridin-2-one en tant qu'inhibiteurs de lipases et de phospholipases
US7846943B2 (en) 2005-06-09 2010-12-07 Sanofi-Aventis Azolopyridin-2-one derivatives as lipase and phospholipase inhibitors
WO2006131233A1 (fr) 2005-06-09 2006-12-14 Sanofi-Aventis Derives de benzooxazol-2-one servant d'inhibiteurs de lipases et de phospholipases
US8357698B2 (en) 2005-10-12 2013-01-22 Sanofi Diacyl indazole derivatives as lipase and phospholipase inhibitors
WO2007042178A1 (fr) * 2005-10-12 2007-04-19 Sanofi-Aventis Derives d'indazole de diacyle constituant des inhibiteurs de lipases et de phospholipases
US7772268B2 (en) 2005-10-12 2010-08-10 Sanofi-Aventis Diacyl indazole derivatives as lipase and phospholipase inhibitors
WO2007045392A1 (fr) * 2005-10-19 2007-04-26 Sanofi-Aventis Derives de triazolopyridine utilises comme inhibiteurs de lipases et de phospholipases
DE102005049954A1 (de) * 2005-10-19 2007-05-31 Sanofi-Aventis Deutschland Gmbh Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen
US7718669B2 (en) 2005-10-19 2010-05-18 Sanofi-Aventis Triazolopyridine derivatives as inhibitors of lipases and phospholipases
US7897616B2 (en) 2006-03-28 2011-03-01 Sanofi-Aventis Imidazopyridin-2-one derivatives as inhibitors of lipases and phospholipases
US8148395B2 (en) 2006-03-28 2012-04-03 Sanofi-Aventis Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2007110215A1 (fr) * 2006-03-28 2007-10-04 Sanofi-Aventis Dérivés d'imidazopyridin-2-one utiles comme inhibiteurs de la lipase endothéliale
WO2007110216A1 (fr) * 2006-03-28 2007-10-04 Sanofi-Aventis Dérivés d'azolopyridin-3-one utiles comme inhibiteurs de la lipase endothéliale
WO2008017381A1 (fr) 2006-08-08 2008-02-14 Sanofi-Aventis Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituée, son procédé de fabrication, médicament contenant ce composé et son utilisation
WO2008122357A1 (fr) * 2007-04-05 2008-10-16 Sanofi-Aventis 5-oxo-isoxazoles utilisés comme inhibiteurs de lipases et de phospholipases
US9029400B2 (en) 2007-04-05 2015-05-12 Sanofi 5-oxoisoxazoles as inhibitors of lipases and phospholipases
US7863279B2 (en) 2007-04-18 2011-01-04 Sanofi-Aventis Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
JP2010524908A (ja) * 2007-04-18 2010-07-22 サノフイ−アベンテイス トリアゾロピリジンカルボキサミド誘導体およびトリアゾロピリミジンカルボキサミド誘導体、これらの調製、ならびにこれらの治療的使用
JP2010524907A (ja) * 2007-04-18 2010-07-22 サノフイ−アベンテイス トリアゾロピリジンカルボキサミド誘導体、その調製およびその治療的使用
JP2010524904A (ja) * 2007-04-18 2010-07-22 サノフイ−アベンテイス トリアゾロピリジンカルボキサミド誘導体およびトリアゾロピリミジンカルボキサミド誘導体、これらの調製、ならびにこれらの治療的使用
US7868007B2 (en) 2007-04-18 2011-01-11 Sanofi-Aventis Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof
WO2008145839A1 (fr) * 2007-04-18 2008-12-04 Sanofi-Aventis Dérivés de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur préparation et leur application en thérapeutique
FR2915198A1 (fr) * 2007-04-18 2008-10-24 Sanofi Aventis Sa Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
FR2915199A1 (fr) * 2007-04-18 2008-10-24 Sanofi Aventis Sa Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
US8080547B2 (en) 2007-04-18 2011-12-20 Sanofi-Aventis Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
WO2008145843A1 (fr) * 2007-04-18 2008-12-04 Sanofi-Aventis Dérivés de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur préparation et leur application en thérapeutique
WO2009021740A2 (fr) 2007-08-15 2009-02-19 Sanofis-Aventis Nouvelles tétrahydronaphtalines substituées, leurs procédés de préparation et leur utilisation comme médicaments
WO2010003624A2 (fr) 2008-07-09 2010-01-14 Sanofi-Aventis Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
WO2011023754A1 (fr) 2009-08-26 2011-03-03 Sanofi-Aventis Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, substances pharmaceutiques comprenant ces composés et leur utilisation
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
WO2011161030A1 (fr) 2010-06-21 2011-12-29 Sanofi Dérivés de méthoxyphényle à substitution hétérocyclique par un groupe oxo, leur procédé de production et leur utilisation comme modulateurs du récepteur gpr40
WO2012004270A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés 1,3-propanedioxyde à substitution spirocyclique, procédé de préparation et utilisation comme médicament
WO2012004269A1 (fr) 2010-07-05 2012-01-12 Sanofi Dérivés d'acide ( 2 -aryloxy -acétylamino) - phényl - propionique, procédé de production et utilisation comme médicament
WO2012010413A1 (fr) 2010-07-05 2012-01-26 Sanofi Acides hydroxy-phényl-hexiniques substitués par aryloxy-alkylène, procédé de production et utilisation comme médicament
WO2012031383A1 (fr) * 2010-09-06 2012-03-15 中国科学院广州生物医药与健康研究院 Composés amide
GB2497476B (en) * 2010-09-06 2018-01-10 Guangzhou Inst Biomed & Health Amide Compounds
US9238643B2 (en) 2010-09-06 2016-01-19 Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences Amide compounds
GB2497476A (en) * 2010-09-06 2013-06-12 Guangzhou Inst Biomed & Health Amide Compounds
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120051A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
WO2012120058A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120057A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120050A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, médicaments contenant ces composés et leur utilisation
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2567959A1 (fr) 2011-09-12 2013-03-13 Sanofi Dérivés d'amide d'acide 6-(4-Hydroxy-phényl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
CN104125956A (zh) * 2011-12-22 2014-10-29 康内克斯生命科学私人有限公司 作为11-β-羟基类固醇脱氢酶的抑制剂的环酰胺及其用途
KR20140127226A (ko) * 2011-12-22 2014-11-03 커넥시오스 라이프 사이언시즈 피브이티. 리미티드 11-베타-하이드록시스테로이드 탈수소효소의 저해제로서 사이클릭 아마이드 유도체 및 이의 용도
KR102083040B1 (ko) 2011-12-22 2020-02-28 커넥시오스 라이프 사이언시즈 피브이티. 리미티드 11-베타-하이드록시스테로이드 탈수소효소의 저해제로서 사이클릭 아마이드 유도체 및 이의 용도
WO2013128465A1 (fr) * 2011-12-22 2013-09-06 Connexios Life Sciences Pvt. Ltd. Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci
US9453014B2 (en) 2011-12-22 2016-09-27 Connexios Life Sciences Pvt. Ltd. Cyclic amide derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase and uses thereof
US11046654B2 (en) 2012-07-24 2021-06-29 Bial-Portela & Ca, S.A. Urea compounds and their use as enzyme inhibitors
US10023541B2 (en) 2012-07-24 2018-07-17 Bial-Portela & Ca, S.A. Urea compounds and their use as enzyme inhibitors
US9549915B2 (en) 2012-07-24 2017-01-24 Bial-Portela & Ca, S.A. Urea compounds and their use as enzyme inhibitors
WO2014017938A3 (fr) * 2012-07-27 2014-03-20 BIAL - PORTELA & Cª, S.A. Procédé pour la synthèse de composés d'urée substitués
US10501447B2 (en) 2013-07-24 2019-12-10 BIAL-PORTELA & Cᵃ, S.A. Imidazolecarboxamides and their use as FAAH inhibitors
US9512122B2 (en) 2013-09-06 2016-12-06 Karos Pharmaceuticals, Inc. Spirocyclic compounds as tryptophan hydroxylase inhibitors
US9750740B2 (en) 2013-09-06 2017-09-05 Kanos Pharmaceuticals, Inc. Spirocyclic compounds as tryptophan hydroxylase inhibitors
US10660893B2 (en) 2013-09-06 2020-05-26 ROIVANT SCIENCES, GmbH Spirocyclic compounds as tryptophan hydroxylase inhibitors
US10045988B2 (en) 2013-09-06 2018-08-14 Roivant Sciences Gmbh Spirocyclic compounds as tryptophan hydroxylase inhibitors
US11759462B2 (en) 2013-09-06 2023-09-19 Altavant Sciences Gmbh Spirocyclic compounds as tryptophan hydroxylase inhibitors
US9199994B2 (en) 2013-09-06 2015-12-01 Karos Pharmaceuticals, Inc. Spirocyclic compounds as tryptophan hydroxylase inhibitors
US10350208B2 (en) 2013-09-06 2019-07-16 Roivant Sciences Gmbh Spirocyclic compounds as tryptophan hydroxylase inhibitors
US10946018B2 (en) 2013-09-06 2021-03-16 Roivant Sciences Gmbh Spirocyclic compounds as tryptophan hydroxylase inhibitors
WO2015035113A1 (fr) 2013-09-06 2015-03-12 Karos Pharmaceuticals, Inc. Composés spirocycliques en tant qu'inhibiteurs de la tryptophane hydroxylase
WO2015089137A1 (fr) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines comme inhibiteurs de la tryptophan hydroxylase
WO2016109501A1 (fr) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Composés amides utilisés en tant qu'inhibiteurs de la tryptophane hydroxylase
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
US10710948B2 (en) 2015-03-05 2020-07-14 Roivant Sciences Gmbh Processes for preparing (R)-1-(5-chloro-[1,1″-biphenyl] -2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1″-biphenyl]-2-yl)-2,2,2-trifluoroethanone
US10266530B2 (en) 2016-09-09 2019-04-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US11242343B2 (en) 2016-09-09 2022-02-08 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US11014929B2 (en) 2016-09-09 2021-05-25 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US11542265B2 (en) 2016-09-09 2023-01-03 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
US11891388B2 (en) 2016-09-09 2024-02-06 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10934288B2 (en) 2016-09-09 2021-03-02 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US11795166B2 (en) 2016-09-09 2023-10-24 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10435405B2 (en) 2016-09-09 2019-10-08 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US11406624B2 (en) 2017-02-15 2022-08-09 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US10800761B2 (en) 2018-02-20 2020-10-13 Incyte Corporation Carboxamide compounds and uses thereof
US11731958B2 (en) 2018-02-20 2023-08-22 Incyte Corporation Carboxamide compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11492354B2 (en) 2018-02-20 2022-11-08 Incyte Corporation Indazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
US11866426B2 (en) 2018-08-08 2024-01-09 Incyte Corporation Benzothiazole compounds and uses thereof
US11111247B2 (en) 2018-09-25 2021-09-07 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2020099929A1 (fr) 2018-11-14 2020-05-22 Roivant Sciences Gmbh Inhibiteur de composé spirocyclique cristallin de tryptophane hydroxylase 1 (tph1) pour le traitement de maladies ou de troubles associés à la sérotonine périphérique
US11787784B2 (en) 2019-08-06 2023-10-17 Incyte Corporation Solid forms of an HPK1 inhibitor
US11066394B2 (en) 2019-08-06 2021-07-20 Incyte Corporation Solid forms of an HPK1 inhibitor

Also Published As

Publication number Publication date
ECSP066750A (es) 2006-11-16
IL176912A0 (en) 2006-12-10
TW200536535A (en) 2005-11-16
UY28735A1 (es) 2005-08-31
KR20060128958A (ko) 2006-12-14
NZ548872A (en) 2010-04-30
HN2005000039A (es) 2008-02-21
JP2007519649A (ja) 2007-07-19
EP1713779B1 (fr) 2011-04-13
JP4714158B2 (ja) 2011-06-29
MY143407A (en) 2011-05-13
DE502005011241D1 (de) 2011-05-26
CN1914180A (zh) 2007-02-14
EP1713779A1 (fr) 2006-10-25
DE102004005172A1 (de) 2005-08-18
ATE505460T1 (de) 2011-04-15
RU2006131564A (ru) 2008-03-10
IL176912A (en) 2011-01-31
US20050197348A1 (en) 2005-09-08
SG149891A1 (en) 2009-02-27
RU2370491C2 (ru) 2009-10-20
CA2554524A1 (fr) 2005-08-11
US7968719B2 (en) 2011-06-28
ZA200605311B (en) 2007-10-31
AU2005209366A1 (en) 2005-08-11
AR047520A1 (es) 2006-01-25
NO20063925L (no) 2006-09-01
BRPI0507370A (pt) 2007-07-10
PE20050690A1 (es) 2005-11-07
DOP2005000011A (es) 2005-11-15
US20090215824A1 (en) 2009-08-27
CR8487A (es) 2007-12-04
US7528155B2 (en) 2009-05-05
MA28338A1 (fr) 2006-12-01

Similar Documents

Publication Publication Date Title
EP1713779B1 (fr) Derives d'indazole utilises comme inhibiteurs de la lipase hormono-sensible
DE102005049954A1 (de) Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen
DE102005048897A1 (de) Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen
EP1874741A1 (fr) Derives d'azole comme inhibiteurs de lipases et de phospholipases
DE102006014688A1 (de) Azolopyridin-3-on-derivate als Inhibitoren von Lipasen und Phospholipasen
DE102006014685A1 (de) Imidazo-pyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholiphasen
DE102005049953A1 (de) Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen
EP1896485B1 (fr) Derives d'azolopyridin-2-one en tant qu'inhibiteurs de lipases et de phospholipases
EP1893590B1 (fr) Dérivés de benzooxazol-2-one servant d'inhibiteurs de lipases et de phospholipases
EP1896435B1 (fr) Derives de benzothiazol-2-one servant d'inhibiteurs de lipases et de phospholipases
MXPA06008406A (en) Indazole derivatives as inhibitors of hormone-sensitive lipases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006/05311

Country of ref document: ZA

Ref document number: 200605311

Country of ref document: ZA

Ref document number: CR2006-008487

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 176912

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005700954

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2554524

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020067015071

Country of ref document: KR

Ref document number: PA/a/2006/008406

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 06074367

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 12006501475

Country of ref document: PH

Ref document number: 548872

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200580003798.4

Country of ref document: CN

Ref document number: 2006549989

Country of ref document: JP

Ref document number: 2005209366

Country of ref document: AU

Ref document number: 2819/CHENP/2006

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005209366

Country of ref document: AU

Date of ref document: 20050115

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005209366

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006131564

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005700954

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067015071

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0507370

Country of ref document: BR